ArticlePloS one2011
Impairment of the Plasmodium falciparum erythrocytic cycle induced by angiotensin peptides.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria.PLoS pathogens · 2014Trial
- Investigating angiotensin II concentration in modulatingFrontiers in parasitology · 2026Article
- Hormones in malaria infection: influence on disease severity, host physiology, and therapeutic opportunities.Bioscience reports · 2024Review
- Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models.Scientific reports · 2024Article
- Pathogenetic mechanisms and treatment targets in cerebral malaria.Nature reviews. Neurology · 2023Review
- Is there a role for bradykinin in cerebral malaria pathogenesis?Frontiers in cellular and infection microbiology · 2023Review
- The mechanistic basis linking cytokine storm to thrombosis in COVID-19.Thrombosis update · 2022Review
- Evolutionary trilogy of malaria, angiotensin II and hypertension: deeper insights and the way forward.Journal of human hypertension · 2022Review
- The monoterpene 1,8-cineole prevents cerebral edema in a murine model of severe malaria.PloS one · 2022Article
- Malaria, COVID-19 and angiotensin-converting enzyme 2: what does the available population data say?Open biology · 2021Review
- Article
- Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes.Reports of biochemistry & molecular biology · 2021Article
- Malaria link of hypertension: a hidden syndicate of angiotensin II, bradykinin and sphingosine 1-phosphate.Human cell · 2021Review
- COVID-19-related complications and decompression illness share main features.: Could the SARS-CoV2-related complications rely on blood foaming?Medical hypotheses · 2020Article
- Malaria and COVID-19: Common and Different Findings.Tropical medicine and infectious disease · 2020Article
- Implications of COVID-19 Pandemic on Evolution of Diabetes in Malaria-Endemic African Region.Journal of diabetes research · 2020Review
- Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?Frontiers in microbiology · 2020Article
- Hypertension is associated with an increased risk for severe imported falciparum malaria: a tertiary care hospital based observational study from Berlin, Germany.Malaria journal · 2019Observational
- Malaria infection promotes a selective expression of kinin receptors in murine liver.Malaria journal · 2019Article
- The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmodium falciparum causes the most serious complications of malaria and is a public health problem worldwide with over 2 million deaths each year. The erythrocyte invasion mechanisms by Plasmodium sp. have been well described, however the physiological aspects involving host components in this process are still poorly understood. Here, we provide evidence for the role of renin-angiotensin system (RAS) components in reducing erythrocyte invasion by P. falciparum. Angiotensin II (Ang II) reduced erythrocyte invasion in an enriched schizont culture of P. falciparum in a dose-dependent manner. Using mass spectroscopy, we showed that Ang II was metabolized by erythrocytes to Ang IV and Ang-(1-7). Parasite infection decreased Ang-(1-7) and completely abolished Ang IV formation. Similar to Ang II, Ang-(1-7) decreased the level of infection in an A779 (specific antagonist of Ang-(1-7) receptor, MAS)-sensitive manner. 10(-7) M PD123319, an AT(2) receptor antagonist, partially reversed the effects of Ang-(1-7) and Ang II. However, 10(-6) M losartan, an antagonist of the AT(1) receptor, had no effect. Gs protein is a crucial player in the Plasmodium falciparum blood cycle and angiotensin peptides can modulate protein kinase A (PKA) activity; 10(-8) M Ang II or 10(-8) M Ang-(1-7) inhibited this activity in erythrocytes by 60% and this effect was reversed by 10(-7) M A779. 10(-6) M dibutyryl-cAMP increased the level of infection and 10(-7) M PKA inhibitor decreased the level of infection by 30%. These results indicate that the effect of Ang-(1-7) on P. falciparum blood stage involves a MAS-mediated PKA inhibition. Our results indicate a crucial role for Ang II conversion into Ang-(1-7) in controlling the erythrocytic cycle of the malaria parasite, adding new functions to peptides initially described to be involved in the regulation of vascular tonus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.